First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study - Soria, J-C; Tan, D SW; Chiari, R (Lancet, 2017)
(10072):